Document is current
Any future updates will be listed below
-
Authors
Turco, Fabio https://orcid.org/0000-0003-3111-7888
Gillessen, Silke https://orcid.org/0000-0001-5746-6555
Salfi, Giuseppe https://orcid.org/0000-0003-4953-0339
Kloots, Iris S. H. https://orcid.org/0000-0001-9181-1359
Slootbeek, Peter H. J. https://orcid.org/0000-0002-5635-919X
Mehra, Niven https://orcid.org/0000-0002-4794-1831
Labriola, Matthew https://orcid.org/0000-0003-0919-9864
George, Daniel J. https://orcid.org/0000-0002-0836-8542
Broderick, Amanda https://orcid.org/0000-0002-6925-3095
Patrikidou, Anna
Patry, Hortense
Buttigliero, Consuelo https://orcid.org/0000-0002-2877-2518
Crespi, Veronica
Uemura, Hirotsugu
Fujita, Kazutoshi
Utsumi, Takanobu
Suzuki, Hiroyoshi
Raggi, Daniele https://orcid.org/0000-0002-4185-2475
Basso, Umberto
Morales-Barrera, Rafael https://orcid.org/0000-0001-7398-0685
Marmolejo Castaneda, David
Sternberg, Cora N. https://orcid.org/0000-0003-3938-2627
Guevara, Daniela https://orcid.org/0000-0002-9428-4125
Caffo, Orazio https://orcid.org/0000-0001-7968-2531
Procopio, Giuseppe
Zivi, Andrea
Merler, Sara https://orcid.org/0000-0002-8691-6284
Sorarù, Mariella https://orcid.org/0000-0001-5198-7755
Spratt, Daniel E. https://orcid.org/0000-0002-5973-4741
C. Barata, Pedro https://orcid.org/0000-0002-8890-2951
Messina, Carlo
ürün, Yüksel
Bolek, Hatice
Duràn, Ignacio
Lavin, Juan Diego Cacho
Martínez Chanzá, Nieves https://orcid.org/0000-0001-8970-911X
Horvath, Lisa G. https://orcid.org/0000-0001-6842-9223
Mellor, Rhiannon
Türkeri, Levent
Soykök, Merve Bengisu
Rossetti, Sabrina
Cathomas, Richard https://orcid.org/0000-0002-9677-9885
Banna, Giuseppe Luigi https://orcid.org/0000-0003-0764-3650
Conteduca, Vincenza https://orcid.org/0000-0002-6921-714X
Ottaviano, Margaret
Marandino, Laura
Lin, Hui-Ming
Tortola, Luigi
Pereira Mestre, Ricardo https://orcid.org/0000-0002-3123-3697
Pedrani, Martino https://orcid.org/0000-0002-8502-8226
- License Information
-
More Information
Article History
Received: 3 January 2026
Revised: 1 April 2026
Accepted: 19 May 2026
First Online: 29 May 2026
Competing interests
: FT reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Silvio Grasso Consulting (institutional), SAKK (institutional), Merck (institutional), Novartis (istitutional), Bayer (individual) and MSD (individual); support for attending meetings or travel from Bayer (individual); and participation on a data safety monitoring board or advisory board for Bayer (individual) and Telix (individual). SG (last 2 years) personal honoraria for invited speaker for Schweizerische Gesellschaft für Medizinische Onkologie (SGMO)/Meister ConCept GmbH; other honoraria from University of Applied Sciences and Arts of Southern Switzerland (SUPSI). Travel grants from Bayer, Gilead, Intellisphere LLC, Johnson & Johnson. Institutional honoraria advisory boards or in Independent Data Monitoring-/Steering Committees from Amgen, Astellas, AstraZeneca, Avalere Health, Bayer, Bristol-Myers Squibb, GSK, Ipsen, LinkinVax, Macrogenics, Merck, MDS Merck Sharp & Dohme, Novartis, Pfizer; invited speaker for Emirates Oncology, EPG Health, ESMO, Intellisphere LLC, Medtoday Switzerland, Orikata, PeerVoice, Pfizer, Schweizerische Gesellschaft für Medizinische Onkologie (SGMO)/Meister ConCept GmbH, Silvio Grasso Consulting, Swiss group for Clinical Cancer Research (SAKK)/Swiss Cancer Institute (SCI), SwissInfoMed, Symposia Congressi, UroPratica Group. Patent for a research method for biomarker WO2009138392. KF reports honoraria for lectures from AstraZeneca, Bayer, Ono, Eisai, MSD, Bristol-Myers Squibb, Takeda, Merk, Astellas, Janssen, and Novartis. HS reports research funding from Astellas, AstraZeneca, Bayer, Chugai, Eli-lily, Janssen, MSD, Nihon Kayaku, and Sanofi; advisory fees from Astra Zeneca, Bayer, Chugai-Roche, Eli Lilly, Ferring, Janssen, MSD, Novartis, Pfizer, and Sanofi; and lecture fees from Astellas, AstraZeneca, Bayer, Janssen, Novartis, Pfizer, and Sanofi. CNS reports Consulting fees: Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Gilead; Merck; MSD; Pfizer; Janssen; Roche; Medscape; UroToday; Tolmar; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Merck; Pfizer GP reports financial Interests: ACCORD Healthcare Italia Srl, Steeering Committee, Personal, consultant fees; Astellas, Advisory Board, Personal, consultant fees; Astrazeneca, Advisory Board, Personal, consultant fees; Amgen, Advisory Board, Personal, consultant fees; Boehringer, Advisory Board, Personal, consultant fees; Bayer, Advisory Board, Personal, consultant fees; Brystol Myers Squibb, Advisory Board, Personal, consultant fees; Ipsen, Advisory Board, Personal, consultant fees; Janssen, Advisory Board, Personal, consultant fees; Eisai, Advisory Board, Personal, consultant fees; Janssen Cilag, Advisory Board, Personal, consultant fees; Merck Sharp & Dohmes, Advisory Board, Personal, consultant fees; Merck, Advisory Board, Personal, consultant fees; Pfizer, Advisory Board, Personal, consultant fees; Roche, Advisory Board, Personal, consultant fees; Eli Lilly, Advisory Board, Personal, consultant fees; Menarini Group, Other, Personal, workgroup; Telix Pharmaceuticals Limited, Advisory Board, Personal, consultant fees; GE Medical Systems Italia SPA, Other, Personal, consultant fees; Ipsen, Research Grant, Institutional, research funding for no profit clinical trial Coordinating PI; Gilead, Research Grant, Institutional, research funding for no profit clinical trial; MSD, Research Grant, Institutional, research funding for no profit clinical trial; Janssen, Research Grant, Institutional, research funding for no profit clinical trial; Board of Directors : ASCO Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer living guideline 2025 MS reports travel support from 2022 Janssen; 2023: Novartis; 2024: Astellas, Ipsen; 2025: Bayer, Novartis DES reports personal Fees: AstraZeneca, Bayer, Boston Scientific, Janssen, Novartis, Pfizer PCB reports grants or personal fees from Astellas; AstraZeneca; Bayer, Eisai; Ipsen; Caris Life Sciences; Exelixis; Janssen, Pfizer, Sanofi, Seattle Genetics, BMS, Bayer, Guardant Health; Caris Life Sciences; Myovant; Medscape; UroToday; MJH Life Sciences CM received fee as speaker in symposia organized by J&j, Astellas, msd, Orion Pharma JDCL reports sonsultant advisory Role: Astrazeneca, BMS; speaking: Astrazneca, BMS, Leopharma, Rovi MCN reports research travel from Pfizer and Ipsen, consulting fees (institutional) from BMS, Bayer, Ipsen and Merck. LGH reports grants or contracts from any entity: astellas (institutional), Bayer (institutional); Consulting fees: Astellas (institutional), Bayer (institutional), Janssen (institutional); Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Astellas (institutional), Bayer (institutional), Janssen (institutional), Amgen (institutional); support for attending meetings and/or travel: Bayer (institutional); patents planned, issued or pending: Australian Patent Application No. 2022902527 International (PCT) Patent Application No. PCT/AU2023/050849 Pending (institutional); Leadership or fiduciary role in other board, society, committee or advocacy group: ANZUP Board (unpaid) RM reports consulting fees: Bayer (individual); Support for attending meetings and/or travel (individual) RC reports advisory role (institutional): MSD, Astra Zeneca, BMS, Merck, Roche, Bayer, Astellas, Janssen, Pfizer, Ipsen, Debiopharm, Accord, Novartis, Sandoz; Speaker role (institutional): Astellas, Janssen, Merck, Ipsen, Accord; Travel support (institutional): Ipsen, Astra Zeneca GLB reports personal fees from advisory boards (Accord, AstraZeneca, Amgen, Merck) and speaker bureaus (Astellas, AstraZeneca, Amgen, Bayer, Merck, Pfizer). Travel/accommodation for scientific conferences: Accord, Merck, Janssen VC has served as a consultant/advisory board member for Johnson&Johnson, Astellas, Merck, AstraZeneca, Amgen, EISAI, Recordati, Novartis, Ipsen, and Bayer and has received speaker honoraria or travel support from Astellas, Johnson&Johnson, Ipsen, Bayer, Gilead, Novartis, GSK and BristolMyers Squibb. HML reports employment with the Garvan Institute of Medical Research, and is a co-inventor of a patent for a prognostic biomarker in prostate cancer (PCT/AU2023/050849). The other authors declared no conflicts of interest.
